NHS Wales partners with Illumina on genomics drive
pharmaphorum
NOVEMBER 8, 2024
Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.
pharmaphorum
NOVEMBER 8, 2024
Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.
pharmaphorum
NOVEMBER 3, 2020
Ring Chromosome 20 Syndrome, or (R)20, is an ultra-rare form of epilepsy with a devastating impact – yet despite huge leaps forward in gene sequencing in recent years, diagnoses are going down instead of up. The post Ring 20: Could the rare disease get left behind by next-generation gene sequencing? appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Reporter
JULY 11, 2023
A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora, Mexico.
pharmaphorum
JUNE 23, 2022
The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.
pharmaphorum
AUGUST 10, 2021
The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma.
XTalks
DECEMBER 14, 2022
The CRISPR-Cas9 gene editing system uses a programmable single guide RNA sequence (sgRNA) to find and bind to specific regions of DNA and the Cas9 nuclease induces double strand breaks at these target regions of the genome. The researchers reported very few unwanted deletions or insertions at the sites of gene integration.
pharmaphorum
JANUARY 5, 2023
and OriCiro Genomics K.K. The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – thought to be driving a patient’s cancer. Biotech Moderna, Inc. The deal marks 10-year-old Moderna’s first acquisition.
Let's personalize your content